Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
agenT-797 +/- ICIs in Advanced Solid Tumors
NCT05108623Phase 1Completed
- Sponsor
- MiNK Therapeutics
- Start
- Jan 2022
- Primary completion
- Jan 2024
- Modality
- Allogeneic CAR-T, Lymphokine-Activated Killer Cells, Autologous CAR-T
- Countries
- 1
01
Overview
Phase 1, open-label trial of agenT-797 in solid tumor (2 arms), sponsored by MiNK Therapeutics. Primary endpoints: Number Of Participants With Treatment-emergent Adverse Events at 12 months, Number Of Adverse Events By The Dose Of iNKT Cell Therapy at 12 months and 1 more. Started Jan 2022; status: completed.
02
Drugs
agenT-797
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05108623.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05108623.